NCT02041429View on ClinicalTrials.gov

Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

May 31, 2016

Study Completion Date

January 31, 2021

Conditions
Recurrent Breast CancerMetastatic Breast Cancer
Interventions
DRUG

Ruxolitinib

DRUG

Paclitaxel

Trial Locations (1)

02215

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Incyte Corporation
All Listed Sponsors
collaborator

Incyte Corporation

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER